Os­man Kibar lays down his hand at Sa­mumed, step­ping away from CEO role as his once-her­ald­ed an­ti-ag­ing biotech re­brands

Sa­mumed made quite the en­trance back in 2016, when it launched with some an­ti-ag­ing pro­grams and a whop­ping $12 bil­lion val­u­a­tion. That lev­el of fan­fare was nowhere to be found on Thurs­day, when the com­pa­ny added an­oth­er $120 mil­lion to its cof­fers and qui­et­ly changed its name to Bios­plice Ther­a­peu­tics.

Why the sud­den re­brand?

“We did that for ob­vi­ous rea­sons,” CFO and CBO Erich Hors­ley told End­points News. “The name Bios­plice echoes our sci­ence much more than Sa­mumed does.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER